Sunrest Lifescience Ltd (SUNREST) — shareholding pattern, promoter holding, financials and share price
About Sunrest Lifescience Ltd (SUNREST)
Sunrest Lifescience Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SUNREST and on the BSE under scrip code 91669. Its ISIN is INE0PLZ01012.
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products [1]
Sunrest Lifescience Limited specializes in marketing OTC generic pharmaceutical products across multiple states in India, such as Maharashtra and Gujarat.
The company recently transitioned from a private to a public entity, marking its ambition for growth and greater market penetration.
Listed peers in Pharmaceuticals: Parmax Pharma Ltd, Medi Caps Ltd, Walpar Nutritions Ltd, Welcure Drugs & Pharmaceuticals Ltd, Chandra Bhagat Pharma Ltd, Medicamen Organics Ltd.
Valuation & Returns
At ₹35 a share, Sunrest Lifescience Ltd (SUNREST) was valued at a price-to-earnings ratio of 8.21x against an industry P/E of 36.41x and a price-to-book of 1.24x on a book value of ₹28.81 per share. Solomo computes return on equity of 20.15% and return on capital employed of 30.12% from filed results.
- P/E
- 8.21x
- Industry P/E
- 36.41x
- P/B
- 1.24x
- EPS (TTM)
- ₹4.66
- Book value / share
- ₹28.81
- ROE
- 20.15%
- ROCE
- 30.12%
- ROA
- 10.11%
- Debt / equity
- 0.85x
- Dividend yield
- 0%
- EBITDA margin
- 16.53%
- 52-week range
- ₹26.37 – ₹54.17
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sunrest Lifescience Ltd (SUNREST) reported revenue of ₹70.83 crore, net profit of ₹8 crore and earnings per share of ₹4.8. That compares with revenue of ₹33.41 crore and net profit of ₹2.02 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹36.82 crore and net profit ₹6.57 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 33.41 | 70.83 |
| Net profit (₹ cr) | 2.02 | 8 |
| EPS (₹) | 2.34 | 4.8 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 24.77% | 7.20% | 12.35% |
| Profit growth | 122.35% | 37.04% | 769.57% |
| Stock price CAGR | - | - | -28% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 53.5% of Sunrest Lifescience Ltd (SUNREST) (unchanged from the previous quarter). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2024.
Largest disclosed public shareholders in Jun 2026: AMIT R AGARWAL 5.18%, PRAKASH GOURISANKAR JHUNJHUNWALA 2.95%, COMELY ELECTRICAL PRIVATE LIMITED 1.86%, RIKHAV SECURITIES LIMITED 1.68%, SHARDABEN DALSUKHRAM THAKKAR 1.49%, MANJU DEVI 1.16%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 53.5% | - | - | - | - |
| Mar 2026 | 53.5% | - | - | - | - |
| Dec 2025 | 53.5% | - | - | - | - |
| Sep 2025 | 53.5% | - | - | - | - |
| Jun 2025 | 69.91% | - | - | - | - |
| Mar 2025 | 69.91% | - | - | - | - |
| Dec 2024 | 69.91% | - | - | - | - |
| Sep 2024 | 69.91% | - | - | - | - |